The Sun Pharmaceutical Industries stock, which witnessed gains after its September quarter (Q2) results, is now trading below the pre-result level, despite the recent positive news flow. The latest development pertains to the restart of supplies of some products to the US by Sun Pharma from its key plant in Halol (Gujarat). A Credit Suisse report, referring to latest IMS data, indicates the firm’s oncology generics of Gleevac has gained market share sequentially in the December quarter (Q3) so far on a trailing basis.
The Gleevac generics, which witnessed ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
First Published: Wed, December 06 2017. 00:55 IST
